key: cord-0716123-j5vyunon authors: Remy-Jardin, Martine; Duthoit, Louise; Perez, Thierry; Felloni, Paul; Faivre, Jean-Baptiste; Fry, Stéphanie; Bautin, Nathalie; Chenivesse, Cécile; Remy, Jacques; Duhamel, Alain title: Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients date: 2021-03-30 journal: EClinicalMedicine DOI: 10.1016/j.eclinm.2021.100778 sha: e3585603884370ae53331d53ccf717fce1e7eb4a doc_id: 716123 cord_uid: j5vyunon BACKGROUND: During COVID-19, the main manifestations of the disease are not only pneumonia but also coagulation disorders. The purpose of this study was to evaluate pulmonary vascular abnormalities 3 months after hospitalization for SARS-CoV-2 pneumonia in patients with persistent respiratory symptoms. METHODS: Among the 320 patients who participated in a systematic follow-up 3 months after hospitalization, 76 patients had residual symptoms justifying a specialized follow-up in the department of pulmonology. Among them, dual-energy CT angiography (DECTA) was obtained in 55 patients. FINDINGS: The 55 patients had partial (n = 40; 72.7%) or complete (n = 15; 27.3%) resolution of COVID-19 lung infiltration. DECTA was normal in 52 patients (52/55; 94.6%) and showed endoluminal filling defects in 3 patients (3/55; 5.4%) at the level of one (n = 1) and two (n = 1) segmental arteries of a single lobe and within central and peripheral arteries (n = 1). DECT lung perfusion was rated as non-interpretable (n = 2;3.6%), normal (n = 17; 30.9%) and abnormal (n = 36; 65.5%), the latter group comprising 32 patients with residual COVID-19 opacities (32/36; 89%) and 4 patients with normal lung parenchyma (4/36; 11%). Perfusion abnormalities consisted of (a) patchy defects (30/36; 83%), (b) PE-type defects (6/36; 16.6%) with (n = 1) or without proximal thrombosis (n = 5); and (c) focal areas of hypoperfusion (2/36; 5.5%). Increased perfusion was seen in 15 patients, always matching GGOs, bands and/or vascular tree-in- bud patterns. INTERPRETATION: DECT depicted proximal arterial thrombosis in 5.4% of patients and perfusion abnormalities suggestive of widespread microangiopathy in 65.5% of patients. Lung microcirculation was abnormal in 4 patients with normal lung parenchyma. Since the onset of the COVID-19 pandemic, the radiological literature has reported the characteristic findings of COVID-19 pneumonia, which most frequently include bilateral, peripheral, often roundedground-glass opacities that are predominantly located in the lower lobes, often accompanied by consolidation [1] . During the acute phase of the disease, case reports and autopsy findings rapidly alerted the medical community on coagulation abnormalities, raising questions on whether thrombotic and embolic events worsened the patient's clinical status [2À6] . This led to modify the indications for chest CT in COVID-19 patients, primarily limited to non-contrast examinations for the evaluation of parenchymal abnormalities or assessment of alternative diagnoses. CT angiography was then considered in the management of patients exhibiting acute or subacute respiratory distress, enabling depiction of endoluminal filling defects in up to 30% of patients, mainly located within segmental and subsegmental arteries [7À12] . Although endoluminal clots could result from a thromboembolic disease, autopsy studies highlighted changes consistent with thrombosis occurring within the pulmonary arterial circulation in the absence of apparent embolism [5] . This was also clinically suggested by the low proportion of patients with PE in whom deep vein thrombosis was diagnosed [8, 9] . The second aspect of the COVID-19 vasculopathy lies at the level of lung microcirculation. Autopsy studies highlighted the severe endothelial injury associated with intracellular virus and disrupted cell membranes with widespread capillary microthrombi [13, 14] . In comparison with autopsy findings in influenza-associated respiratory failure, alveolar capillary microthrombi were found to be 9 times more prevalent in patients with COVID-19 who also exhibited a 2.7 times higher amount of new vessel growth [13] . In-vivo insight into this distal pulmonary angiopathy was reported in patients with mild to severe COVID-19 pneumonia who underwent dual-energy CT angiography [15À20]. In the early clinical phase, increased lung perfusion matching with ground-glass opacities was reported. At a later phase of the disease, widespread perfusion defects were described in a majority of patients as well as halos of increased perfusion surrounding hypoperfused areas of consolidation, the latter suggesting the detectability of microvascular changes within areas of COVID-19 pneumonia. Complex interactions between ventilation and perfusion are also to be considered. A mathematical model has recently raised hypotheses on the combined effects of pulmonary embolism, ventilation-perfusion mismatching in the non-injured lung and normal perfusion of the relatively small fraction of injured lung to explain early COVID-19 hypoxemia [21] . Although the long-term outcome of vascular changes is still unknown, the state of perfusion of lung tissue at the different phases of COVID-19 pneumonia appears to be an important parameter for a proper understanding of physiological derangements [22] . The primary objective of the present study was to investigate the morphologic and perfusion changes within pulmonary circulation three months after hospitalization for COVID-19 pneumonia in a cohort of 55 patients with persistent respiratory symptoms who underwent dual-energy (DE) CT angiography. The secondary objective was to search for differences in patient characteristics according to the results of DECT perfusion imaging. All patients who had been hospitalized for COVID-19 pneumonia confirmed by RT-PCR analysis of throat specimens between March and April 2020 in our center were offered a systematic follow-up at 3 months by the Department of Infectious Diseases. The criteria for hospitalization included the presence of dyspnea, a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pa02:FiO 2 ) of less than 300 mm Hg and/or infiltrates in more than 50% of the lung field. There were two broad categories of hospitalized patients: (a) patients with a critical respiratory status, justifying to be admitted in the ICU; and (b) patients in less severe conditions, requiring management in a non-ICU department. At the time of follow-up ( Fig. 1) , 76 patients presenting with residual respiratory symptoms (i.e., dyspnea, dry cough) and/or concern on chest radiographic abnormalities were referred to the Department of Pulmonology for specialized follow-up. The pulmonologists in charge of COVID-19 follow-up considered that 9 patients did not require further evaluation as their residual symptoms and/or chest radiographic abnormalities did not differ from those observed before COVID-19, explained by a pre-existing underlying respiratory disease. The clinical presentation of the remaining 67 patients justified further investigation with chest CT angiography (CTA) and pulmonary function tests (PFTs). All patients underwent chest CT that could not be obtained with administration of contrast material due to renal insufficiency in 7 patients. Five patients underwent singleenergy CTA in a community center only equipped with this technology and 55 patients underwent a dual-energy CT angiographic study in our department. Because lung perfusion is only available on dualenergy chest CT angiographic examinations, our study population was limited to these 55 patients. All patients underwent chest CT which consisted of non-contrast examinations (n = 7; renal insufficiency), single-energy (n = 5) and dual-energy (n = 55) (DECT) CT angiographic studies. The subgroup of 55 patients with DECT angiographic follow-up was the study population of this investigation. PFTs were available in 46 patients (84%) and not performed in 9 patients (16%) (patient refusal: n = 3; equipment not available Evidence before this study During COVID-19, the main manifestations of the disease are not only pneumonia but also coagulation disorders. Based on literature review that included CT angiographic examinations, endoluminal filling defects were detected in up to 30% of patients, mainly located within segmental and subsegmental arteries. Although endoluminal clots could result from a thromboembolic disease, autopsy studies highlighted changes consistent with thrombosis occurring within the pulmonary arterial circulation in the absence of apparent embolism. This was also clinically suggested by the low proportion of patients with PE in whom deep vein thrombosis was diagnosed. The second aspect of the COVID-19 vasculopathy lies at the level of lung microcirculation. Autopsy studies highlighted the severe endothelial injury associated with intracellular virus and disrupted cell membranes with widespread capillary microthrombi. Patients with COVID-19 also exhibited a high amount of new vessel growth When CT angiography was obtained with dual-energy (DE), standard CT angiographic images were completed by lung perfusion images enabling analysis of lung microcirculation. In the early clinical phase, increased lung perfusion matching with ground-glass opacities was reported. At a later phase of the disease, widespread perfusion defects were described in a majority of patients as well as halos of increased perfusion surrounding hypoperfused areas of consolidation, the latter suggesting the detectability of microvascular changes within areas of COVID-19 pneumonia. This is the first study reporting pulmonary circulation status in the follow-up of COVID-19 survivors remaining symptomatic 3 months after hospitalization for a severe SARS-CoV-2 pneumonia. Dual-energy CT (DECT) angiography depicted unexpected proximal arterial thrombosis in 5.4% of patients DECT lung perfusion abnormalities suggestive of widespread microangiopathy were identified in 65.5% of patients. In addition to perfusion defects, perfusion imaging also allowed depiction of areas increased perfusion matching residual SARS-CoV-2 pneumonia abnormalities. This study suggests the presence of multiple residual changes within central and peripheral pulmonary circulation in the months following COVID-19 pneumonia that can help understand patient functional complaint. It also highlights the persistent risk for pulmonary artery thrombosis. at the time of CT examination: n = 6). The study population included consecutive patients requiring follow-up with retrospective analysis of data. All data used in this study were retrieved from patient files (clinical, biological, functional and therapeutic data); CT images were accessible via the PACS system; all data were available for clinical research purposes. This retrospective, non-interventional observational study was approved by the local Ethics Committee (Comit e de Protection des Personnes Nord Ouest IV, registered in the Office for Human Research Protection Database IORG 0,009,553) with vaiwer of patient informed consent according to national and European regulatory rules and general data protection regulation (GDPR). This study was conducted in agreement with the French law of August 9, 2004, completed by the law n°2012À300 of March 5, 2012 . No industrial support was given to the authors. The aim of the study was to investigate the morphologic and perfusion changes within pulmonary circulation three months after hospitalization for COVID-19 pneumonia in a cohort of 55 patients with persistent respiratory symptoms who underwent dual-energy (DE) CT angiography. The primary endpoint was to analyze the presence of endoluminal clots within pulmonary arteries and abnormalities of lung microcirculation on DECT iodine maps. Because DECT lung perfusion cannot be interpreted without precise knowledge of lung parenchymal status, this investigation also included the analysis of corresponding lung images with special evaluation of residual abnormalities of the COVID-19 pneumonia and potential presence of comorbid conditions such as emphysema and interstitial lung disease. Secondary endpoints investigated whether differences in patient characteristics could be observed according to the results of DECT perfusion imaging. The study population underwent a dual-energy CT angiographic (CTA) examination on a 3rd-generation dual-source CT system (Somatom Force, Siemens Healthineers, Forchheim, Germany) with injection of 60 À 90 mL of a 40% iodinated contrast material at a rate of 3À4 mL/sec. From each data set, three series of images were generated: (a) contiguous, 1 mm thick lung and mediastinal images, reconstructed with high resolution and soft kernels (Bl 57 and Br 36, respectively); and 1-mm thick lung perfusion images using the Lung PBV software (Siemens Healthineers, Forchheim, Germany).This was completed by a second set of perfusion images, generated by subtraction of low-and high-monoenergetic images, to generate less noisy images in this population mainly composed of overweight and obese patients. This was obtained on the eXamine prototype (Siemens Healthineers, Forchheim, Germany). The percentage of COVID-19 lung infiltration, further referred to as the "CT COVID score" was calculated using an AI-software prototype (CT Pneumonia Analysis; Siemens Healthineers, Forchheim, Germany). The algorithm uses CT data to automatically identify and 3Dsegment both the lung parenchyma and abnormal areas of groundglass opacities and consolidation. The software outputs a percentage of total lung involvement (by both GGO and consolidation) [23] . Follow-up chest CTA was systematically completed by a volumetric, non-contrast, single-energy acquisition at expiration to detect air trapping, i.e., a potential confounder for perfusion defect interpretation. Pulmonary arterial circulation was analyzed on mediastinal and perfusion images. On mediastinal images, we searched for the presence of endoluminal filling defects from central to subsegmental arterial divisions. On perfusion images, we rated the presence of: (a) perfusion defects of 3 types: patchy defects, PE-type defects and nonsystematized areas of hypoperfusion; and (b) areas of increased perfusion. The iodine concentration, expressed in mg of iodine per mL of lung volume, was calculated for both lungs. On lung images, we recorded the presence and extent of post COVID-19 abnormalities, including ground-glass opacities, bands, consolidation and features of fibrosis (i.e., honeycomb cysts) or features potentially suggestive of fibrosis (i.e., bronchial and/or bronchiolar dilatation within areas of ground-glass opacities and/or reticulation). Their distribution was rated as unilateral/bilateral; central/peripheral. We also searched for the presence of vascular features described in the acute phase of COVID-19 pneumonia, i.e., the "vascular tree-in-bud" pattern and abnormally dilated peripheral vessels [17] . The presence, extent and severity of comorbid conditions that might interfere with CT lung perfusion analysis, i.e., emphysema and interstitial lung disease, was also recorded. Emphysema was rated as mild when limited to centrilobular emphysema, moderate when lung destruction was more pronounced but without reaching the level of panlobular emphysema, and severe in presence of panlobular emphysema. The extent of emphysema was rated as limited when involving exclusively the upper lobes, and diffuse when observed from to bottom of the lungs. ILD was rated as fibrosing or non-fibrosing, and limited (<10% of the lung volume) or diffuse in distribution. Air trapping was searched for on expiratory scans. Pulmonary function tests included a spirometry with forced vital capacity (FVC) and slow vital capacity (VC), plethysmographic lung volumes and a single-breath DLCO according to ATS/ERS guidelines and the 1993 ERS predicted values were used [24, 25] . The list of PFT parameters comprised vital capacity, forced vital capacity, forced expiratory volume in one second, forced residual capacity, residual volume, total lung capacity, diffusing capacity of the lung for carbon monoxide and alveolar capillary blood volume. The primary objective of this study was to investigate the morphologic and perfusion changes within pulmonary circulation three months after hospitalization for COVID-19 pneumonia. The endpoints for the primary objective were the presence of endoluminal filling defects within central and peripheral pulmonary arteries on morphologic images and the presence of perfusion abnormalities, including perfusion defects and areas of increased perfusion, on perfusion images. On lung images, we searched for CT features suggestive of residual COVID-19 lung infiltration and the presence of any co-morbid conditions, unrelated to COVID-10 sequellae, that could alter lung perfusion. The secondary objective was to search for differences in patients'characteristics according to the results of DECT perfusion images. The endpoints for this secondary objective concerned the patients' status at the time of the early phase of COVID-19 pneumonia, the pulmonary function profile, the quantitiative analysis of the iodine content on perfusion images. The reading of morphologic and perfusion imaging was obtained by consensus between two senior chest radiologists with 7 and 14 years of experience in DECT lung perfusion analysis, respectively. A separate analysis of lung, mediastinal and perfusion images, presented in random order, was first undertaken. A second reading session was organized with a combined reading of lung and perfusion images of each patient to superimpose perfusion abnormalities on the corresponding morphological background. Categorical variables are expressed as number and percentages. Continuous variables were reported as means and standard deviations (SD) in the case of normal distribution or medians (interquartile, IQR) otherwise. Normality of distributions was assessed using histograms and the Shapiro-Wilk test. Comparisons of clinical data and PFTs between patients with normal and abnormal lung perfusion were performed with the Mann-Whitney test for quantitative variables and the chi-square test (or Fisher exact test) for categorical variables. The condition of validity of the chi-square test (all expected values greater or equal to 5) was checked. We did not perform comparisons when a group included less than 10 patients. Statistical testing was conducted at the two-tailed ⍺-level of 0.05 and was considered as an exploratory analysis. Data were analyzed using the SAS software version 9.4 (SAS Institute Inc, Cary, NC 25,513). No funding was received for this work As shown in Table 1 , the study population of 55 patients (42 males; 13 females; mean age: 59.7 year) included 24 smokers (43.6%) and 11 patients (20.0%) had respiratory comorbidities. The median BMI was 27.1 kg/m 2 ; the study group was mainly composed of overweight (n = 21; 38.2%) and obese (n = 19; 34.5%). Table 2 summarizes the clinical and biological data of the study population at the time of COVID-19 lung infection: (a) 23 patients (41.8%) had been admitted to the ICU; (b) COVID-19 imaging was obtained by chest X-ray alone in 20 patients (36.3%) and completed by chest CT in 35 patients (63.7%) with a mean ( § SD) score of COVID-19 lung abnormalities of 34.0% ( § 23.7); (c) acute PE was diagnosed in the absence of major predisposing factors in 5 patients (9.1%); (d) 36 patients (65.5%) received prophylactic anticoagulation. The standard of care proposed in our institution at the time of early COVID-19 pandemic included the following therapeutic options, i.e., probabilistic antibiotherapy, systemic corticotherapy and/or anticoagulation while antiviral therapy was only administered to patients who accepted to be enrolled in the European DISCOVERY trial. Details for our study population is given in Table 2 . The median (interquartile range) interval of time between COVID-19 and follow-up CTA was 144.0 (Q1; Q3: 121.0; 157.0) days. Fortysix patients underwent PFTs within 8 days after CTA. Functional parameters are summarized in Table 3 . The mean ( §SD) DLCO was 78.6 § 16.1%. Emphysema was identified in 10 patients (severe: n = 1; moderate: n = 2; mild: n = 7), diffusely distributed in 3 patients and exclusively seen in the upper lobes in 7 patients. Two patients had CT features of basal and peripheral fibrosing ILD involving <10% of lung volume. In 3 patients (3/55; 5.4%), endoluminal filling defects were identified at the level of: (a) one (n = 1) and two (n = 1) segmental pulmonary arteries of a single lobe; these filling defects were nonobstructive; and (b) central and peripheral pulmonary arteries of both lungs (n = 1); they consisted of multiple obstructive and nonobstructive endoluminal filling defects. Lung parenchymal images of the 3 patients showed residual COVID-19 lung abnormalities, mostly represented by disseminated ground glass attenuation and a few basal bands; there were no CT features of recent lung infarction. Following CT angiography, Doppler ultrasonographic examination was obtained; none of these patients had deep venous thrombosis. At the time of acute viral infection: (a) none of these patients had pulmonary artery thrombosis;(b) they did not receive preventive anticoagulation during the hospitalization. Perfusion images were (a) non-interpretable in 2/55 patients (3.6%), owing to marked artifacts in the context of morbid obesity and/or shoulder prosthetic material; (b) normal in 17 patients (30.9%); and (c) abnormal in 36 patients (65.5%). Perfusion abnormalities consisted of a variable association of: (a) patchy perfusion defects (30/36; 83%), seen as disseminated abnormalities;(b) PE-type perfusion defects (6/36; 16.6%) in presence (n = 1) or absence of proximal thrombosis (n = 5); multiple segmental and subsegmental defects were seen in both lungs in the patient with multiple endoluminal clots (Fig. 2) ; a few (1À5 defects/patient), peripheral and small-sized (